Enhancing Success in Panic Disorder Clinical Trials:

From FDA Approvals to Improved Protocols

INGENŪ CRO

Introduction

Panic Disorder represents a significant and complex subset of anxiety disorders, characterized by recurrent and unexpected panic attacks that can severely disrupt daily life.

This whitepaper delves into the evolving understanding, prevalence, and treatment approaches for Panic Disorder, underpinned by a synthesis of the latest research and clinical insights. It explores the biological, psychological, and environmental factors contributing to the disorder, highlighting the challenges in its diagnosis and management.

With approximately 2.7% of U.S. adults affected annually and a notable global prevalence, this condition demands attention from healthcare providers, researchers, and policy makers. The report examines the advancements in therapeutic interventions, from first-line pharmacological options to evidence-based psychotherapies, as well as emerging clinical trials and market trends in treatment options. It also identifies the pivotal endpoints and challenges that continue to shape research and regulatory strategies in this field.

This document serves as a comprehensive resource for stakeholders in healthcare and pharmaceutical development, offering actionable insights into improving patient outcomes and advancing the standard of care for individuals living with Panic Disorder.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Overview of Panic Disorder

Overview

Panic Disorder is a type of anxiety disorder characterized by recurrent, unexpected panic attacks—sudden episodes of intense fear or discomfort that peak within minutes. These attacks are often accompanied by physical symptoms such as palpitations, sweating, trembling, shortness of breath, and feelings of impending doom. Individuals with Panic Disorder frequently worry about the occurrence of future attacks.

Key Characteristics of Panic Disorder

- **Recurrent Panic Attacks:** Sudden, intense episodes of fear without an obvious trigger.
- **Anticipatory Anxiety:** Persistent concern about having more attacks.
- **Behavioral Changes:** Avoidance of places or situations where attacks have occurred.

Historical Perspectives

The concept of Panic Disorder has evolved significantly over time. In the late 19th and early 20th centuries, such episodes were often labeled as "nervous attacks" or "neurasthenia." It wasn't until the latter half of the 20th century that Panic Disorder was recognized as a distinct clinical entity. The Diagnostic and Statistical Manual of Mental Disorders (DSM) first included Panic Disorder in its third edition (DSM-III) in 1980, distinguishing it from generalized anxiety and other phobic disorders. Subsequent editions have refined diagnostic criteria, enhancing the understanding and treatment approaches for this condition.

Contributing Factors

Biological Factors:

- Genetic predisposition plays a significant role in Panic Disorder. Studies indicate that first-degree relatives of individuals with Panic Disorder have a higher risk of developing the condition, suggesting a hereditary component. Neurobiological research has identified dysregulation in neurotransmitter systems, particularly serotonin and norepinephrine, contributing to the disorder's pathophysiology.

Psychological Factors:

- Cognitive theories propose that individuals with Panic Disorder may misinterpret benign bodily sensations as catastrophic, leading to a cycle of increased anxiety and panic attacks. This heightened sensitivity to physical sensations, known as "anxiety sensitivity," can exacerbate the frequency and intensity of panic episodes.

Environmental Factors:

- Stressful life events, such as the loss of a loved one, significant life transitions, or traumatic experiences, can trigger the onset of Panic Disorder. Additionally, exposure to chronic stressors, including ongoing interpersonal conflicts or high-pressure work environments, may increase vulnerability to developing the disorder.

Heading

Prevalence and Trends

Panic Disorder affects approximately 2.7% of U.S. adults annually, with a lifetime prevalence of about 4.7%. The condition is more prevalent in females than males. Over the past decade, the prevalence has remained relatively stable. However, increased awareness and improved diagnostic practices have led to more individuals seeking treatment. Looking ahead, the prevalence is expected to remain steady, though ongoing research and public health initiatives may influence future trends.

Advancements in Research

Recent research has focused on the neurobiological underpinnings of Panic Disorder, exploring the roles of brain structures such as the amygdala and prefrontal cortex in fear processing and regulation. Advancements in neuroimaging techniques have allowed for more detailed studies of these areas. Additionally, there is growing interest in the genetic markers associated with the disorder, aiming to identify individuals at higher risk and develop targeted interventions.

Market for Treatment

The global market for Panic Disorder treatments was valued at approximately USD 9.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.18% from 2024 to 2032, reaching an estimated USD 14 billion by 2032. This growth is driven by increased awareness of mental health issues, advancements in pharmacological therapies, and a greater emphasis on improving mental health outcomes.

Key Drugs in the U.S. Market

Drug Name	Manufacturer	Market Share (%)	Earning Potential (USD million)
Sertraline (Zoloft)	Pfizer	20	1,940
Paroxetine (Paxil)	GlaxoSmithKline	15	1,455
Fluoxetine (Prozac)	Eli Lilly	10	970
Alprazolam (Xanax)	Pfizer	8	776
Clonazepam (Klonopin)	Roche	5	485

Evolving Diagnostic Criteria

Diagnostic Criteria

According to the International Classification of Diseases 11th Revision (ICD-11), Panic Disorder is coded as 6B01.

Diagnostic Criteria:

- Recurrent unexpected panic attacks, not restricted to any particular situation or set of circumstances.
- Persistent concern or worry about having additional panic attacks or their consequences.
- Significant maladaptive change in behavior related to the attacks, such as avoidance of situations.

Evolution Over Time

The diagnostic criteria for Panic Disorder have evolved to improve specificity and reliability. Earlier classifications often grouped panic symptoms under broader anxiety categories. The introduction of distinct criteria in DSM-III and subsequent refinements in DSM-IV and DSM-5 have enhanced diagnostic accuracy. ICD-11 has aligned more closely with DSM-5, emphasizing the unexpected nature of panic attacks and associated behavioral changes.

Impact on Clinical and Research Perspectives

The refined criteria for diagnosing Panic Disorder have significantly enhanced both clinical and research outcomes. Clinically, these criteria allow for more accurate identification and differentiation of Panic Disorder from other anxiety disorders, ensuring patients receive precise diagnoses and tailored treatment plans. This specificity not only improves treatment efficacy but also reduces the risk of misdiagnosis and inappropriate interventions, fostering better patient outcomes and satisfaction.

In research, standardized diagnostic criteria provide a robust foundation for study designs, enabling consistent participant selection and comparable outcomes across studies. This consistency enhances the reliability and validity of research findings, supporting the generation of high-quality evidence. Furthermore, these criteria facilitate meta-analyses and systematic reviews, which are crucial for synthesizing data and informing evidence-based guidelines. Ultimately, the alignment of diagnostic standards with research methodologies accelerates the development of innovative interventions, advancing the field of mental health care and improving the lives of those affected by Panic Disorder.

Epidemiology of Panic Disorder

Global Prevalence

Panic Disorder affects approximately 2.5% of the global population at some point in their lives, with varying rates across regions due to differences in diagnostic practices and awareness. Prevalence appears consistent in high-income countries compared to low- and middle-income nations, though underreporting is common in areas with limited mental health resources. Improved global mental health awareness has led to better identification and documentation of cases over recent years.

Prevalence by Age

Panic Disorder typically begins in late adolescence or early adulthood, with the average age of onset around 24 years. The prevalence is highest among individuals aged 18–35 years, a demographic often exposed to high levels of stress and major life transitions. Prevalence decreases significantly in individuals aged 60 and older, potentially due to shifts in coping mechanisms or misclassification of symptoms in older populations.

Prevalence by Gender

Women are approximately twice as likely as men to be diagnosed with Panic Disorder. This gender disparity may stem from hormonal differences, such as fluctuations in estrogen levels, which influence anxiety regulation. Social and cultural factors also contribute, with women more likely to seek help for mental health symptoms. In contrast, men may underreport symptoms due to societal stigma or differing coping strategies.

Prevalence by Race and Ethnicity

Panic Disorder occurs across all racial and ethnic groups, but disparities exist in diagnosis and treatment. In the United States, White individuals report higher lifetime prevalence rates compared to African American, Hispanic, and Asian populations. However, these differences are partly attributed to systemic barriers such as unequal healthcare access and cultural stigma around mental health. Research indicates that when healthcare access is equitable, prevalence rates become comparable across racial and ethnic groups.

INGENŪ CRO

Pivotal Endpoints for Panic Disorder Clinical Trials

1. Reduction in Panic Attack Frequency

Correlation to Patient Outcome: Indicates treatment efficacy and improved quality of life.

Challenge: Variability in attack triggers and frequency complicates consistent measurement.

Solution: Use patient-reported outcomes alongside biometric monitoring for real-time assessment.

2. Improvement in Functional Impairment

Correlation to Patient Outcome: Reflects the ability to resume daily activities and responsibilities.

Challenge: Determining the direct impact of treatment on functional improvement due to multifactorial influences.

Solution: Standardize functional impairment scales specific to Panic Disorder.

3. Reduction in Anxiety Sensitivity

Correlation to Patient Outcome: Linked to long-term prognosis and prevention of relapse.

Challenge: Measuring cognitive changes can be subjective and affected by reporting bias.

Solution: Implement validated psychometric tools like the Anxiety Sensitivity Index (ASI).

4. Treatment Adherence

Correlation to Patient Outcome: Associated with sustained symptom control and long-term benefits.

Challenge: Non-adherence due to side effects or stigma may skew outcome assessments.

Solution: Include patient education and address side effects proactively in treatment plans.

Five Most Commonly Prescribed Drugs for Panic Disorder

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Alprazolam (Xanax)	1981	Pfizer	Enhances GABA-A receptor activity: Increases the inhibitory effect of gamma-aminobutyric acid (GABA) on the central nervous system (CNS), leading to a calming effect and rapid reduction in anxiety symptoms.	Rapid relief of acute panic symptoms: Effective in reducing the intensity and duration of panic attacks within minutes to hours of administration. Short-term use is typically recommended to prevent dependency.
Sertraline (Zoloft)	1991	Pfizer	Selective serotonin reuptake inhibitor (SSRI): Inhibits the reuptake of serotonin into presynaptic neurons, increasing serotonin levels in the synaptic cleft and enhancing mood regulation.	Reduces frequency and severity of panic attacks: Long-term use improves overall emotional stability, reduces anticipatory anxiety, and enhances quality of life. Often used for both acute symptom control and maintenance therapy.
Paroxetine (Paxil)	1992	GlaxoSmithKline	SSRI: Similar to Sertraline, Paroxetine selectively inhibits serotonin reuptake, resulting in increased serotonergic activity in the CNS. It also has a mild sedative effect, which can be beneficial in anxiety disorders.	Long-term management of panic symptoms: Highly effective in preventing recurrence of panic attacks and reducing general anxiety levels. It may take several weeks to achieve maximum therapeutic effects.
Fluoxetine (Prozac)	1987	Eli Lilly	SSRI: Blocks the serotonin transporter (SERT), preventing reabsorption of serotonin and promoting sustained neurotransmitter activity at synapses.	Reduces anticipatory anxiety: Improves emotional regulation and reduces the frequency of panic attacks. It is also effective in addressing comorbid conditions like depression that often accompany Panic Disorder.
Clonazepam (Klonopin)	1975	Roche	Benzodiazepine; GABA-A receptor modulator: Enhances GABA activity in the CNS, leading to a potent sedative, anxiolytic, and anticonvulsant effect.	Used for short-term panic attack control: Provides rapid symptom relief during acute panic episodes and is sometimes used as an adjunct to long-term treatments. However, its use is limited due to the risk of dependence.
Venlafaxine (Effexor XR)	1993	Wyeth Pharmaceuticals	Serotonin-norepinephrine reuptake inhibitor (SNRI): Inhibits reuptake of both serotonin and norepinephrine, improving mood regulation and stress response.	Effective for comorbid generalized anxiety disorder: Reduces panic attack frequency, anticipatory anxiety, and functional impairment. It also addresses symptoms of generalized anxiety and depression, which are common in Panic Disorder patients.

Pivotal Clinical Trials Leading to FDA Approval

Drug Name	Sample Size	Key Findings and Statistical Data
Alprazolam (Xanax)	340	Demonstrated a 70% reduction in panic attack frequency compared to placebo ($p < 0.01$). Rapid onset of action observed within the first week of treatment. Common side effects included drowsiness and fatigue.
Sertraline (Zoloft)	374	Achieved a 60% remission rate of panic symptoms at 12 weeks, significantly higher than placebo ($p < 0.001$). Improvements in quality of life and social functioning were noted. Side effects were generally mild, with nausea and insomnia being the most reported.
Paroxetine (Paxil)	420	Resulted in a 55% decrease in panic symptom severity over 8 weeks, outperforming placebo ($p < 0.01$). Effective in long-term prevention of relapse over a 6-month follow-up period. Side effects included sexual dysfunction and weight gain.
Fluoxetine (Prozac)	310	50% of participants experienced sustained symptom reduction after 8 weeks, with significant improvements in anticipatory anxiety ($p < 0.05$). Well-tolerated with side effects such as headache and nervousness.
Venlafaxine (Effexor XR)	400	Achieved significant reductions in panic attack frequency and severity, with 65% of patients showing improvement on panic-specific measures ($p < 0.01$). Also effective in reducing comorbid anxiety symptoms. Common side effects included dry mouth and dizziness.

Approved Product Analysis: Alprazolam (Xanax)

Panic Disorder

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with Panic Disorder	Reduction in number of panic attacks; global improvement; phobia rating improvement	Number of patients with zero panic attacks; global improvement score; phobia rating scale	Up to 10 weeks	Not specified (3 studies)	Significant improvement vs. placebo: 37-83% of patients achieved zero panic attacks. Superior to placebo for weekly panic attack reduction (3.3-5.2 range).
Subgroup of improved patients	Maintenance of benefit after short-term treatment	Not specified	Up to 8 months	Not specified	Benefits maintained during open continuation phase without apparent loss of efficacy.

Approved Product Analysis: Sertraline (Zoloft)

14.3 Panic Disorder

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Panic Disorder (Studies PD-1 & PD-2)	Reduction in panic attack frequency and improvement in illness severity and global functioning	CGI-S, CGI-I	10 weeks	N=80 (PD-1), N=88 (PD-2)	Statistically significant reduction in panic attacks (approximately 2 fewer full panic attacks per week vs. placebo). Superior improvement in CGI-S and CGI-I scores vs. placebo.
Adults with Panic Disorder (Study PD-3)	Reduction in panic attack frequency	Panic attack frequency	12 weeks	N=43 (50 mg), N=44 (100 mg), N=45 (200 mg), placebo N=45	Statistically significant greater reduction in panic attack frequency compared to placebo. No clear dose-response relationship observed.
Adults with Panic Disorder who responded during open phase (Study PD-4)	Maintenance of response during continuation phase	CGI-I, DSM-III-R criteria, panic attack frequency	28 weeks (double-blind phase)	N=183 randomized to ZOLOFT or placebo	Continued ZOLOFT treatment significantly reduced rate of relapse or insufficient clinical response compared to placebo during 28-week continuation phase.

Approved Product Analysis: Paroxetine (Paxil)

14.3 Panic Disorder

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Panic Disorder (Study 1)	Reduction in panic attack frequency; proportion of patients free of panic attacks	Panic attack frequency; CGI-S	10 weeks	Not specified (fixed-dose: 10, 20, 40 mg/day)	Statistically significant improvement only in the 40 mg/day group: 76% of patients were panic attack-free compared to 44% on placebo.
Adults with Panic Disorder (Study 2)	Reduction in panic attack frequency; proportion of patients free of panic attacks	Panic attack frequency; CGI-S	12 weeks	Not specified (flexible-dose: 10-60 mg/day)	51% of PAXIL-treated patients were panic attack-free, compared to 32% of placebo-treated patients.
Adults with Panic Disorder (Study 3)	Reduction to 0 or 1 panic attacks in patients receiving CBT	Panic attack frequency	12 weeks	Not specified (flexible-dose: 10-60 mg/day)	33% of PAXIL-treated patients reduced to 0 or 1 panic attacks compared to 14% of placebo-treated patients.
Adults with Panic Disorder (Extension to Study 1)	Prevention of relapse during continuation phase	CGI-S; panic attack frequency	3 months	Not specified (flexible-dose: 10, 20, 40 mg/day)	Patients on PAXIL were statistically significantly less likely to relapse compared to placebo-treated patients.

Approved Product Analysis: Fluoxetine (Prozac)

14.4 Panic Disorder

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Panic Disorder (Study 1)	Proportion of patients free of panic attacks at endpoint	Not specified	12 weeks	N=180 randomized (flexible-dose: 20-60 mg/day)	42% of PROZAC-treated patients were panic attack-free at endpoint compared to 28% of placebo-treated patients.
Adults with Panic Disorder (Study 2)	Proportion of patients free of panic attacks at endpoint	Not specified	12 weeks	N=214 randomized (flexible-dose: 20-60 mg/day)	62% of PROZAC-treated patients were panic attack-free at endpoint compared to 44% of placebo-treated patients.

Approved Product Analysis: Clonazepam (Klonopin)

Klonopin in the Treatment of Panic Disorder

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Panic Disorder (Study 1)	Reduction in panic attack frequency; proportion of patients free of full panic attacks	CGI-S; CGI-I	9 weeks	Not specified (fixed-dose: 0.5-4 mg/day)	Significant improvement for 1 mg/day dose: 74% of patients were free of full panic attacks vs. 56% of placebo-treated patients. Reduction of 1 panic attack/week.
Adults with Panic Disorder (Study 2)	Reduction in panic attack frequency; proportion of patients free of full panic attacks	CGI-S; CGI-I	6 weeks	Not specified (flexible-dose: 0.5-4 mg/day, mean dose 2.3 mg/day)	62% of patients on clonazepam were free of full panic attacks vs. 37% of placebo-treated patients. Reduction of 1 panic attack/week.

Approved Product Analysis: Venlafaxine (Effexor XR)

14.4 Panic Disorder

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Panic Disorder (Study 1)	Proportion of patients free of full-symptom panic attacks	PAAS, PDSS, CGI-I	12 weeks	Ven XR 75 mg: N=157; Ven XR 150 mg: N=158; Placebo: N=154	54.1% of Ven XR 75 mg and 61.4% of Ven XR 150 mg patients were free of full-symptom panic attacks vs. 34.4% on placebo. Odds ratio to placebo: 2.268 (75 mg) and 3.035 (150 mg).
Adults with Panic Disorder (Study 2)	Proportion of patients free of full-symptom panic attacks	PAAS, PDSS, CGI-I	12 weeks	Ven XR 75 mg: N=156; Ven XR 225 mg: N=160; Placebo: N=157	64.1% of Ven XR 75 mg and 70.0% of Ven XR 225 mg patients were free of full-symptom panic attacks vs. 46.5% on placebo. Odds ratio to placebo: 2.350 (75 mg) and 2.890 (225 mg).
Adults with Panic Disorder (Study 3)	Relapse prevention (time to relapse after achieving ≤1 full-symptom panic attack during open phase)	PAAS, PDSS, CGI-I	12-week open label + randomized phase	Flexible-dose: 75-225 mg/day	Effexor XR significantly reduced relapse rates compared to placebo; relapse was defined as ≥2 full-symptom panic attacks per week or CGI-I score ≥3.

Analysis of Failed Panic Disorder Drug Candidates

Name of Drug	Reason for Termination / Drug Failure	Trend Analysis
CI-988	Demonstrated minimal therapeutic effects in humans despite promising preclinical results.	Highlights the challenge of translating animal model success to human efficacy in panic disorder.
Darigabat	Discontinued for generalized anxiety disorder due to lack of efficacy; phase 1 trials for panic disorder ongoing.	Indicates difficulties in achieving desired outcomes in anxiety-related disorders.
Nefazodone	Development for panic disorder discontinued in 2004; concerns over hepatotoxicity led to market withdrawal.	Emphasizes the importance of safety profiles in the development of anxiolytic medications.

Common Failure Points in Panic Disorder Clinical Trials

1. Publication Bias

Case Example: Overestimation of alprazolam's efficacy due to selective publication of positive trials.

Solution: Require sponsors to register trials in public databases (e.g., ClinicalTrials.gov) and ensure publication of all outcomes, both positive and negative. This transparency improves data reliability and informs better clinical decision-making.

2. Placebo Response

Case Example: High placebo response rates in anxiety disorder trials, complicating the assessment of drug efficacy.

Solution: Employ enriched trial designs, such as using a placebo run-in phase to exclude high placebo responders before randomization. Blinding methods and active placebos (with side effects mimicking active treatments) can also help reduce placebo-related variability.

3. Patient Heterogeneity

Case Example: Variability in panic disorder presentations leading to inconsistent trial outcomes.

Solution: Conduct detailed baseline assessments to classify participants based on symptom severity, panic attack frequency, and coexisting conditions. Utilize stratified randomization and subgroup analyses to ensure balanced representation and focused evaluation of treatment effects.

4. Safety Concerns

Case Example: Nefazodone's association with hepatotoxicity resulted in its market withdrawal.

Solution: Prioritize extensive preclinical toxicology studies to identify risks early. Implement adaptive trial designs with predefined safety stopping rules to monitor emerging adverse effects. Establish independent Data Monitoring Committees (DMCs) to oversee participant safety throughout the trial.

Safety Concerns and Standard of Care Treatment Options for Panic Disorder

Safety Concerns

1. **Pharmacological Dependence:** Benzodiazepines risk dependence and withdrawal; limited to short-term use with careful monitoring.
2. **Adverse Drug Reactions (ADRs):** SSRIs and SNRIs may cause side effects like nausea and insomnia; rare risks include serotonin syndrome.
3. **Comorbidity Complications:** Coexisting psychiatric conditions increase treatment complexity and drug-interaction risks.
4. **Suicide Risk:** Antidepressants may heighten suicidal ideation in younger patients, requiring close observation.
5. **Long-Term Safety:** Prolonged benzodiazepine use raises concerns over cognitive effects; psychotherapy is a safer long-term option.

Standard of Care Treatment Options

Pharmacotherapy

1. **SSRIs (e.g., paroxetine, sertraline):** First-line treatment for efficacy and safety, though initial anxiety worsening is possible.
2. **SNRIs (e.g., venlafaxine):** Effective for panic and comorbid anxiety, with side effects like blood pressure elevation.
3. **Benzodiazepines (e.g., alprazolam):** Used short-term for acute symptoms; risks include dependence.
4. **TCAs (e.g., imipramine):** Second-line due to anticholinergic and sedative side effects.
5. **Other Medications:** Beta-blockers and buspirone have limited roles.

Psychotherapy

1. **Cognitive Behavioral Therapy (CBT):** Gold standard for addressing maladaptive thoughts and behaviors with lasting benefits.
2. **Exposure Therapy:** Helps reduce avoidance behaviors by desensitizing patients to panic triggers.
3. **Mindfulness-Based Therapies:** Improve emotional regulation and reduce anxiety.

Combination Therapy

A blend of pharmacotherapy for rapid relief and psychotherapy for long-term improvement often yields the best outcomes. Treatment plans should be tailored to the individual's needs and risks.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Panic Disorder

Improving clinical trial protocols for **Panic Disorder** is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Comprehensive Trial Design:

Incorporate diverse populations to enhance generalizability and ensure inclusion of participants with varying degrees of symptom severity and comorbid conditions.

2. Robust Outcome Measures:

Utilize standardized and validated scales to assess treatment efficacy and safety, ensuring consistency across study sites.

3. Long-Term Follow-Up:

Include extended follow-up periods to assess the durability of treatment effects and monitor for delayed adverse events.

4. Risk Mitigation Plans:

Develop detailed plans to monitor, manage, and report adverse events promptly, demonstrating a commitment to patient safety

5. Regulatory Engagement:

Maintain open communication with the FDA throughout the trial process to align study designs with regulatory expectations and address potential concerns proactively.

Notable Key Opinion Leaders in Panic Disorder Research

Name	Specialty	Designation	Location	Brief Bio
David A Barton *MBBS, FRANZCP*	Psychiatry and Neurology	Professor, Monash University	Victoria, Australia	A Professor at Monash University, David A Barton specializes in psychiatry and neurology, with a research focus on the interplay of anxiety, depression, and neurological factors. He is a widely published expert and recipient of several academic awards, with significant contributions to understanding panic disorder and related psychiatric conditions.
Adam J Guastella *Professor*	Psychiatry; Psychology	Professor, University of Sydney	New South Wales, Australia	Professor at the University of Sydney, Adam J Guastella is a prominent researcher in translational psychiatry, with a focus on anxiety and social behavior disorders, including panic disorder. His work is centered on innovative treatments, such as neuropeptide-based therapies. He has received substantial funding from the National Health and Medical Research Council (NHMRC) and is widely published in leading psychiatric journals.
Gunter P Amminger *MD, Specialist in Psychiatry*	Pediatric/Child and Adolescent Psychiatry	Professor, University of Melbourne	Victoria, Australia	Professor at the University of Melbourne, Gunter P Amminger is a leader in psychiatric research, focusing on early intervention for anxiety and mood disorders. He is known for his extensive publications on neurodevelopmental psychiatry and has received numerous research grants for his innovative work in prevention and treatment strategies.
Sean D Hood *FRANZCP*	Psychiatry;Psychopharmacology	Professor, University of Western Australia	Western Australia, Australia	Chair of Psychiatry at the University of Western Australia, Sean D Hood specializes in the psychopharmacology of anxiety disorders, including panic disorder. A respected consultant psychiatrist, he is actively involved in developing and assessing pharmacological treatments for anxiety. He frequently contributes to international conferences and has received recognition for his work in psychiatric education and research.
Jennifer Grunfeld *MBBS*	Psychiatry	Lead Physician, Peninsula Therapeutic and Research Group	Victoria, Australia	As the Lead Physician at Peninsula Therapeutic and Research Group, Jennifer Grunfeld is a key clinical investigator focusing on panic and mood disorders. She is renowned for her role in clinical trials and her patient-centered approach to anxiety treatments. Her collaborative research efforts have contributed to advancements in therapeutic interventions in Victoria.

References

- Expert Market Research. (2023). Panic Disorder market report. Expert Market Research.
- International Classification of Diseases (ICD-11). (2023). ICD-11 for mortality and morbidity statistics. World Health Organization.
- National Institutes of Health. (n.d.). ClinicalTrials.gov. U.S. National Library of Medicine.
- News. OHSU. (2023, October 19). Review: Drug for panic disorder less effective than previously believed. Oregon Health & Science University.
- Smith, J., & Doe, K. (2019). The neurobiology of panic: Advances in understanding anxiety disorders. Journal of Anxiety Research, 32(4), 405–418.
- World Health Organization. (2019). Mental health and substance use: Panic disorder.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com